Sterile solutions that are intended for instillation into the eye. It does not include solutions for cleaning eyeglasses or CONTACT LENS SOLUTIONS.
Substances added to pharmaceutical preparations to protect them from chemical change or microbial action. They include ANTI-BACTERIAL AGENTS and antioxidants.
Derivatives of benzene in which one or more hydrogen atoms on the benzene ring are replaced by bromine atoms.
Analogs or derivatives of prostaglandins F that do not occur naturally in the body. They do not include the product of the chemical synthesis of hormonal PGF.
Dibenzoxepins are heterocyclic compounds consisting of a seven-membered oxepin ring fused with two benzene rings, which have been used as building blocks in the synthesis of various pharmaceutical agents, including some antidepressants and antipsychotics.
A mixture of alkylbenzyldimethylammonium compounds. It is a bactericidal quaternary ammonium detergent used topically in medicaments, deodorants, mouthwashes, as a surgical antiseptic, and as a as preservative and emulsifier in drugs and cosmetics.
A synthetic prostaglandin F2alpha analog. The compound has luteolytic effects and is used for the synchronization of estrus in cattle.
Benzophenones are synthetic organic compounds characterized as aromatic ketones, often used in chemical synthesis for various applications including sunscreen formulations due to their UV-absorbing properties.
The homogeneous mixtures formed by the mixing of a solid, liquid, or gaseous substance (solute) with a liquid (the solvent), from which the dissolved substances can be recovered by physical processes. (From Grant & Hackh's Chemical Dictionary, 5th ed)
The administration of therapeutic agents drop by drop, as eye drops, ear drops, or nose drops. It is also administered into a body space or cavity through a catheter. It differs from THERAPEUTIC IRRIGATION in that the irrigate is removed within minutes, but the instillate is left in place.
Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475)
Purulent infections of the conjunctiva by several species of gram-negative, gram-positive, or acid-fast organisms. Some of the more commonly found genera causing conjunctival infections are Haemophilus, Streptococcus, Neisseria, and Chlamydia.
Inflammation of the eyelids.
The presence of organisms, or any foreign material that makes a drug preparation impure.
A beta-adrenergic antagonist similar in action to PROPRANOLOL. The levo-isomer is the more active. Timolol has been proposed as an antihypertensive, antiarrhythmic, antiangina, and antiglaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor.
The pressure of the fluids in the eye.
The relative equivalency in the efficacy of different modes of treatment of a disease, most often used to compare the efficacy of different pharmaceuticals to treat a given disease.
The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example.
The mucous membrane that covers the posterior surface of the eyelids and the anterior pericorneal surface of the eyeball.
The transparent anterior portion of the fibrous coat of the eye consisting of five layers: stratified squamous CORNEAL EPITHELIUM; BOWMAN MEMBRANE; CORNEAL STROMA; DESCEMET MEMBRANE; and mesenchymal CORNEAL ENDOTHELIUM. It serves as the first refracting medium of the eye. It is structurally continuous with the SCLERA, avascular, receiving its nourishment by permeation through spaces between the lamellae, and is innervated by the ophthalmic division of the TRIGEMINAL NERVE via the ciliary nerves and those of the surrounding conjunctiva which together form plexuses. (Cline et al., Dictionary of Visual Science, 4th ed)
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.
A condition in which the intraocular pressure is elevated above normal and which may lead to glaucoma.
Stratified squamous epithelium that covers the outer surface of the CORNEA. It is smooth and contains many free nerve endings.
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions.They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.
The organ of sight constituting a pair of globular organs made up of a three-layered roughly spherical structure specialized for receiving and responding to light.
An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)
A species of the genus MACACA which typically lives near the coast in tidal creeks and mangrove swamps primarily on the islands of the Malay peninsula.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
Visualization of a vascular system after intravenous injection of a fluorescein solution. The images may be photographed or televised. It is used especially in studying the retinal and uveal vasculature.
The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.
The action of a drug that may affect the activity, metabolism, or toxicity of another drug.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Solutions having the same osmotic pressure as blood serum, or another solution with which they are compared. (From Grant & Hackh's Chemical Dictionary, 5th ed & Dorland, 28th ed)
Homogeneous liquid preparations that contain one or more chemical substances dissolved, i.e., molecularly dispersed, in a suitable solvent or mixture of mutually miscible solvents. For reasons of their ingredients, method of preparation, or use, they do not fall into another group of products.
Elements of limited time intervals, contributing to particular results or situations.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.

Bacteriologic cure of experimental Pseudomonas keratitis. (1/873)

Two long-term therapy trials with high concentrations of antibiotic were carried out to determine the duration of therapy required to achieve bacteriologic cure of experimental Pseudomonas keratitis in guinea pigs. In the first study, corneas still contained Pseudomonas after 4 days of continual topical therapy with either tobramycin 400 mg/ml, amikacin 250 mg/ml, ticarcillin 400 mg/ml, or carbenicillin 400 mg/ml. In an 11-day trial of topical therapy with tobramycin 20 mg/ml, 34 of 36 corneas grew no Pseudomonas after 6 or more days of therapy. The bacteriologic response to therapy in this model occurred in two phases. About 99.9% or more of the organisms in the cornea were killed in the first 24 hr of therapy. The numbers of bacteria remaining in the cornea declined gradually over the next several days until the corneas were sterile. Optimal antibiotic therapy may include two stages: initial intensive therapy with high concentrations of antibiotic applied frequently to achieve a large rapid decrease in numbers of organisms in the cornea, followed by prolonged, less intensive therapy to eradicate organisms and prevent relapse.  (+info)

Latrunculin-A causes mydriasis and cycloplegia in the cynomolgus monkey. (2/873)

PURPOSE: To determine the effect of latrunculin (LAT)-A, which binds to G-actin and disassembles actin filaments, on the pupil, accommodation, and isolated ciliary muscle (CM) contraction in monkeys. METHODS: Pupil diameter (vernier calipers) and refraction (coincidence refractometry) were measured every 15 minutes from 0.75 to 3.5 hours after topical LAT-A 42 microg (approximately 10 microM in the anterior chamber [AC]). Refraction was measured every 5 minutes from 0.5 to 1.5 hours after intracameral injection of 10 microl of 50 microM LAT-A (approximately 5 microM in AC), with intramuscular infusion of 1.5 mg/kg pilocarpine HCl (PILO) during the first 15 minutes of measurements. Pupil diameter was measured at 1 and 2 hours, and refraction was measured every 5 minutes from 1 to 2 hours, after intravitreal injection of 20 microl of 1.25 mM LAT-A (approximately 10 microM in vitreous), with intramuscular infusion of 1.5 mg/kg PILO during the first 15 minutes of measurements (all after topical 2.5% phenylephrine), and contractile response of isolated CM strips, obtained <1 hour postmortem and mounted in a perfusion apparatus, to 10 microM PILO +/- LAT-A was measured at various concentrations. RESULTS: Topical LAT-A of 42 microg dilated the pupil without affecting refraction. Intracameral LAT-A of 5 microM inhibited miotic and accommodative responses to intramuscular PILO. Intravitreal LAT-A of 10 microM had no effect on accommodative or miotic responses to intramuscular PILO. LAT-A dose-dependently relaxed the PILO-contracted CM by up to 50% at 3 microM in both the longitudinal and circular vectors. CONCLUSIONS: In monkeys, LAT-A causes mydriasis and cycloplegia, perhaps related to its known ability to disrupt the actin microfilament network and consequently to affect cell contractility and adhesion. Effects of LAT-A on the iris and CM may have significant physiological and clinical implications.  (+info)

Latrunculin-A increases outflow facility in the monkey. (3/873)

PURPOSE: To determine the effect of Latrunculin (LAT)-A, a macrolide that binds to G-actin, which leads to the disassembly of actin filaments, on shape, junctions, and the cytoskeleton of cultured bovine aortic endothelial cells (BAECs) and on outflow facility in living monkeys. METHODS: Latrunculin-A dose-time-response relationships in BAECs were determined by immunofluorescence and phase contrast light microscopy, facility by two-level constant pressure anterior chamber perfusion. RESULTS: In BAECs, LAT-A caused dose- and incubation time- dependent destruction of actin bundles, cell separation, and cell loss. Cell-cell adhesions were more sensitive than focal contacts. Recovery was also dose- and time-dependent. In monkeys, exchange intracameral infusion and topical application of LAT-A induced dose- and time-dependent several-fold facility increases. The facility increase was completely reversed within several hours after drug removal. However, for at least 24 hours after a single topical LAT-A dose, perfusion with drug-free solution caused an accelerated increase in facility beyond that attributed to normal resistance washout. CONCLUSIONS: Pharmacological disorganization of the actin cytoskeleton in the trabecular meshwork by specific actin inhibitors like LAT-A may be a useful antiglaucoma strategy.  (+info)

Effect of staurosporine on outflow facility in monkeys. (4/873)

PURPOSE: To determine the effect of the serine-threonine kinase inhibitor staurosporine on outflow facility in living monkeys. METHODS: Total outflow facility was determined by two-level constant pressure perfusion of the anterior chamber bilaterally before and after intracameral infusion of staurosporine or vehicle in opposite eyes. RESULTS: Intracameral staurosporine dose-dependently doubled outflow facility, with 0.1 microM, 1 microM, and 10 microM being subthreshold, effective, and maximal doses, respectively. At 50 microM, intracameral staurosporine was less effective than 10 microM on facility and induced corneal toxicity. CONCLUSIONS: The broad-spectrum protein kinase inhibitor staurosporine increases outflow facility in living monkeys, perhaps by affecting the trabecular meshwork cytoskeleton.  (+info)

Population pharmacokinetics of 2% topical dorzolamide in the aqueous humor of humans. (5/873)

PURPOSE: To evaluate the concentration and kinetics of dorzolamide in the aqueous humor after its topical application. METHODS: Samples of aqueous humor were collected at the beginning of routine cataract surgery at defined intervals after topical application of a 2% solution of dorzolamide. After deep-frozen storage of the samples, drug extraction was achieved with a mixture of solvents. Quantification was carried out by high-performance liquid chromatography on a reversed-phase column. RESULTS: Peak concentrations of dorzolamide in aqueous humor were reached approximately 2 hours after application with 1000 ng/ml. Average values were approximately 1000 to 700 ng/ml after 4 to 6 hours and approximately 200 ng/ml after 12 hours. Mean half-life of absorption was 1.2 hours and for elimination 3.0 hours. CONCLUSIONS: Pharmacokinetics of dorzolamide in the aqueous humor of humans are in comparable dimensions as previously reported in experimental trials in pigmented rabbits. There is a clear linear absorption and elimination kinetic, which is demonstrated using the Bateman function. A better knowledge of the distribution and kinetics of dorzolamide will help to explain its reported effects on intraocular hemodynamics, distinct from its intraocular pressure lowering effect.  (+info)

The use of topical aqueous suppressants in the prevention of postoperative intraocular pressure elevation following pars plana vitrectomy with long-acting gas tamponade. (6/873)

PURPOSE: To determine if topical aqueous suppressant therapy applied after pars plana vitrectomy (PPV) with gas tamponade successfully prevents postoperative elevation of intraocular pressure (IOP). METHODS: A prospective, controlled study was performed on patients who met inclusion criteria and underwent PPV with gas tamponade (SF6 18%-20% or C3F8 12%-16%) over a 1-year period. Treatment eyes received topical aqueous suppressants at the end of surgery. Postoperative IOP checks were performed at 4 to 6 hours, 1 day, and 1 week. RESULTS: Twenty-one control (C) and 20 treatment (T) eyes met the inclusion criteria. The IOP (in mm Hg) measured at 4 to 6 hours (23.05 [C], 14.73 [T] and 1 day (23.24 [C], 17.28 [T]) postoperatively showed a statistically significant difference between the groups (P = .0038) at 4 to 6 hours, and a trend toward significance (P = .057) at 1 day. Eleven control and 3 treatment eyes had an IOP spike above 25 mm Hg at 4 to 6 hours or 1 day postoperatively (P = .02), and 6 control and 1 treatment eye had a postoperative IOP above 30 mm Hg. A pressure rise above 40 mm Hg was seen in 2 control eyes and no treatment eyes. CONCLUSIONS: Use of topical aqueous suppressants following PPV with long-acting gas tamponade is effective in preventing significant postoperative IOP elevation in a majority of cases.  (+info)

Long-term ultrastructural changes in human corneas after tattooing with non-metallic substances. (7/873)

AIM: To investigate the ultrastructural appearance and the deposition pattern of dye particles in long term non-metallic corneal tattooing. METHODS: Two tattooed human corneas were obtained by keratoplasty. One corneal button was fixed in Karnovsky's solution and the other in Trumps' solution. Both corneas were divided and processed for conventional light (LM) and transmission electron microscopy (TEM). Five additional formalin fixed corneas with tattoos were retrieved from paraffin for TEM. The time between tattoo and removal of the corneal button/enucleation ranged from 7 to 61 years. All seven corneas were examined using a Jeol JCXA733 microprobe for wave length dispersive analysis in order to exclude any presence of metallic salts in the tattooed area. RESULTS: Histologically, clumps of brown-blackish granules were present mainly in the mid stroma, but also in anterior and partially in the posterior half of the stroma. On TEM, numerous round and oval electron dense particles were seen in the cytoplasm of keratocytes arranged as clusters or large islands. The larger particles appeared black, while the smaller particles were grey. In well fixed tissue a unit membrane was observed around these clusters. No granules were detected in the extracellular matrix. CONCLUSIONS: Keratocytes can actively ingest and retain tattooing particles of non-metallic dyes within their cell membrane for very long periods of time.  (+info)

Treatment of dry eye by autologous serum application in Sjogren's syndrome. (8/873)

AIM: To evaluate the efficacy of autologous serum application for the treatment of dry eye in Sjogren's syndrome. METHODS: The stability of essential components (EGF, vitamin A, and TGF-beta) in preserved serum were examined following preservation at 4 degrees C and -20 degrees C. In a primary clinical trial, 12 patients with Sjogren's syndrome were treated with autologous serum (diluted to 20% with sterile saline) for 4 weeks, and vital staining of the ocular surface was compared before and after treatment. The effects of serum on mucin (MUC-1) expression were observed in cultured conjunctival epithelial cells in vitro. RESULTS: EGF, vitamin A, and TGF-beta were well preserved for up to 1 month in the refrigerator at 4 degrees C and up to 3 months in the freezer at -20 degrees C. Rose bengal and fluorescein scores improved significantly from the initial scores of 5.3 and 5.6 to 1.7 and 2.5 after 4 weeks, respectively. The additive effect of human serum for cultured conjunctival epithelial cells showed significant MUC-1 upregulation on the cell surface. CONCLUSION: Autologous serum application is a safe and efficient way to provide essential components to the ocular surface in the treatment of dry eye associated with Sjogren's syndrome.  (+info)

Ophthalmic solutions are sterile, single-use or multi-dose preparations in a liquid form that are intended for topical administration to the eye. These solutions can contain various types of medications, such as antibiotics, anti-inflammatory agents, antihistamines, or lubricants, which are used to treat or prevent ocular diseases and conditions.

The pH and osmolarity of ophthalmic solutions are carefully controlled to match the physiological environment of the eye and minimize any potential discomfort or irritation. The solutions may be packaged in various forms, including drops, sprays, or irrigations, depending on the intended use and administration route.

It is important to follow the instructions for use provided by a healthcare professional when administering ophthalmic solutions, as improper use can lead to eye injury or reduced effectiveness of the medication.

Pharmaceutical preservatives are substances that are added to medications, pharmaceutical products, or biological specimens to prevent degradation, contamination, or spoilage caused by microbial growth, chemical reactions, or environmental factors. These preservatives help extend the shelf life and ensure the stability, safety, and efficacy of the pharmaceutical formulation during storage and use.

Commonly used pharmaceutical preservatives include:

1. Antimicrobials: These are further classified into antifungals (e.g., benzalkonium chloride, chlorhexidine, thimerosal), antibacterials (e.g., parabens, phenol, benzyl alcohol), and antivirals (e.g., phenolic compounds). They work by inhibiting the growth of microorganisms like bacteria, fungi, and viruses.
2. Antioxidants: These substances prevent or slow down oxidation reactions that can degrade pharmaceutical products. Examples include ascorbic acid (vitamin C), tocopherols (vitamin E), sulfites, and butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT).
3. Chelating agents: These bind to metal ions that can catalyze degradation reactions in pharmaceutical products. Ethylenediaminetetraacetic acid (EDTA) is an example of a chelating agent used in pharmaceuticals.

The choice of preservative depends on the type of formulation, route of administration, and desired shelf life. The concentration of the preservative should be optimized to maintain product stability while minimizing potential toxicity or adverse effects. It is essential to conduct thorough safety and compatibility studies before incorporating any preservative into a pharmaceutical formulation.

Bromobenzenes are a group of chemical compounds that consist of a benzene ring (a cyclic structure with six carbon atoms and alternating double bonds) substituted with one or more bromine atoms. The simplest and most common member of this group is bromobenzene itself, which contains a single bromine atom attached to a benzene ring.

Other members of the bromobenzenes family include dibromobenzene (with two bromine atoms), tribromobenzene (with three bromine atoms), and tetrabromobenzene (with four bromine atoms). These compounds are used in various industrial applications, such as in the production of flame retardants, dyes, pharmaceuticals, and agrochemicals.

It is important to note that bromobenzenes can be harmful or toxic to humans and other organisms, and should be handled with care. Exposure to high levels of these compounds can cause a range of health effects, including irritation of the skin, eyes, and respiratory tract, headaches, dizziness, nausea, and damage to the liver and kidneys.

Prostaglandins F (PGF) are a type of prostaglandin, which are naturally occurring hormone-like substances that have various effects on the body. They are produced in response to injury or infection and play a role in inflammation, fever, and pain. Prostaglandins F are synthesized for medical use and are available as drugs known as dinoprost and cloprostenol.

Dinoprost is a synthetic form of PGF2α (prostaglandin F2 alpha) used to induce labor and treat postpartum hemorrhage. It works by causing the uterus to contract, helping to expel the placenta and reduce bleeding.

Cloprostenol is a synthetic form of PGF2α used in veterinary medicine as a reproductive hormone to synchronize estrus cycles in cattle and sheep, as well as to induce parturition (giving birth) in cows. It works by stimulating the contraction of the uterus and promoting the release of luteinizing hormone (LH), which triggers ovulation.

It is important to note that these synthetic prostaglandins should only be used under the supervision of a healthcare professional or veterinarian, as they can have side effects and interactions with other medications.

Dibenzoxepins are a class of organic compounds that contain a seven-membered ring consisting of two benzene rings fused to an oxygen atom. This structure is a heterocyclic compound, and dibenzoxepins are aromatic in nature. They can be found in some natural sources, but many dibenzoxepin derivatives are synthesized for use in pharmaceuticals and other applications.

In the medical field, certain dibenzoxepin derivatives have been explored for their potential therapeutic benefits. For instance, some of these compounds have shown promise as anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing) agents. Additionally, some dibenzoxepin derivatives are being investigated for their potential use in treating neurological disorders such as depression, anxiety, and schizophrenia due to their ability to interact with various neurotransmitter systems in the brain.

It is important to note that while these compounds have shown promise in preclinical studies, further research is needed to establish their safety and efficacy in humans before they can be approved as medications. Additionally, individual dibenzoxepin derivatives may have different properties, indications, and side effects, so it's essential to consult medical literature or healthcare professionals for specific information on each compound.

Benzalkonium compounds are a group of related chemicals that have antimicrobial properties. They are commonly used as disinfectants and preservatives in various products such as eye drops, nasal sprays, skin creams, and household cleaners. Benzalkonium compounds work by disrupting the cell membranes of bacteria, fungi, and viruses, leading to their death. They are often used in low concentrations and are generally considered safe for topical use, but they can cause irritation and allergic reactions in some people. Prolonged or frequent use of products containing benzalkonium compounds may also lead to the development of bacterial resistance.

Cloprostenol is a synthetic prostaglandin analog used primarily in veterinary medicine for the treatment and prevention of various conditions. The main therapeutic uses of Cloprostenol include:

1. Induction of parturition (labor) in cows, helping to synchronize calving in managed herds.
2. Termination of pregnancy in cattle, especially in cases where the fetus is nonviable or the pregnancy poses a risk to the animal's health.
3. Treatment of uterine and oviductal disorders, such as pyometra (infection of the uterus) and salpingitis (inflammation of the oviduct), in cattle and pigs.
4. Prevention of postpartum disorders, like endometritis (inflammation of the lining of the uterus) and mastitis (inflammation of the mammary glands), by promoting uterine involution and improving overall reproductive performance in cattle.
5. Control of estrus (heat) in cattle, as an aid in estrous synchronization programs for artificial insemination.

Cloprostenol is available in various formulations, such as intramuscular or subcutaneous injectable solutions, and is typically administered by a veterinarian or trained personnel. It is important to note that the use of Cloprostenol and other prostaglandin analogs should be carried out under the guidance and supervision of a veterinary professional, as improper usage can lead to adverse effects or complications.

Benzophenones are a class of chemical compounds that consist of a diphenylmethane structure with a carbonyl group attached to the central carbon atom. They are known for their ability to absorb ultraviolet (UV) light and are often used as UV absorbers or photoinitiators in various applications, such as plastics, coatings, and personal care products.

In the medical field, benzophenones may be used in topical medications as sunscreen agents or in pharmaceutical formulations as photostabilizers to prevent drug degradation caused by UV light exposure. However, some benzophenones have been found to have potential endocrine-disrupting properties and may pose health concerns at high levels of exposure. Therefore, their use is regulated in certain applications, and alternative sunscreen agents are being explored.

In the context of medical terminology, "solutions" refers to a homogeneous mixture of two or more substances, in which one substance (the solute) is uniformly distributed within another substance (the solvent). The solvent is typically the greater component of the solution and is capable of dissolving the solute.

Solutions can be classified based on the physical state of the solvent and solute. For instance, a solution in which both the solvent and solute are liquids is called a liquid solution or simply a solution. A solid solution is one where the solvent is a solid and the solute is either a gas, liquid, or solid. Similarly, a gas solution refers to a mixture where the solvent is a gas and the solute can be a gas, liquid, or solid.

In medical applications, solutions are often used as vehicles for administering medications, such as intravenous (IV) fluids, oral rehydration solutions, eye drops, and topical creams or ointments. The composition of these solutions is carefully controlled to ensure the appropriate concentration and delivery of the active ingredients.

Instillation, in the context of drug administration, refers to the process of introducing a medication or therapeutic agent into a body cavity or onto a mucous membrane surface using gentle, steady pressure. This is typically done with the help of a device such as an eyedropper, pipette, or catheter. The goal is to ensure that the drug is distributed evenly over the surface or absorbed through the mucous membrane for localized or systemic effects. Instillation can be used for various routes of administration including ocular (eye), nasal, auricular (ear), vaginal, and intra-articular (joint space) among others. The choice of instillation as a route of administration depends on the drug's properties, the desired therapeutic effect, and the patient's overall health status.

Anti-allergic agents, also known as antihistamines, are a class of medications used to treat allergies. They work by blocking the action of histamine, a substance in the body that is released during an allergic reaction and causes symptoms such as itching, sneezing, runny nose, and watery eyes.

There are two main types of antihistamines: first-generation and second-generation. First-generation antihistamines, such as diphenhydramine (Benadryl) and chlorpheniramine (Chlor-Trimeton), can cause drowsiness and other side effects, such as dry mouth and blurred vision. They are typically used for the treatment of short-term symptoms, such as those caused by seasonal allergies or a mild reaction to an insect bite.

Second-generation antihistamines, such as loratadine (Claritin) and cetirizine (Zyrtec), are less likely to cause drowsiness and other side effects. They are often used for the long-term treatment of chronic allergies, such as those caused by dust mites or pet dander.

In addition to their use in treating allergies, antihistamines may also be used to treat symptoms of motion sickness, insomnia, and anxiety. It is important to follow the instructions on the label when taking antihistamines and to talk to a healthcare provider if you have any questions or concerns about using these medications.

Bacterial conjunctivitis is a type of conjunctivitis (inflammation of the conjunctiva) that is caused by bacterial infection. The most common bacteria responsible for this condition are Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae.

The symptoms of bacterial conjunctivitis include redness, swelling, and pain in the eye, along with a thick, sticky discharge that can cause the eyelids to stick together, especially upon waking up. Other symptoms may include tearing, itching, and sensitivity to light. Bacterial conjunctivitis is highly contagious and can spread easily through contact with infected individuals or contaminated objects such as towels, handkerchiefs, or makeup.

Treatment for bacterial conjunctivitis typically involves the use of antibiotic eye drops or ointments to eliminate the infection. In some cases, oral antibiotics may also be prescribed. It is important to seek medical attention if you suspect that you have bacterial conjunctivitis, as untreated infections can lead to serious complications such as corneal ulcers and vision loss.

Blepharitis is a common inflammatory condition that affects the eyelids, specifically the eyelash follicles and the edges of the eyelids (called the "eyelid margins"). It can cause symptoms such as redness, swelling, itching, burning, and a crusty or flaky buildup on the lashes. Blepharitis can be caused by a variety of factors, including bacterial infection, skin disorders like seborrheic dermatitis or rosacea, and meibomian gland dysfunction. It is often a chronic condition that requires ongoing treatment to manage symptoms and prevent recurrence.

Drug contamination refers to the presence of impurities or foreign substances in a pharmaceutical drug or medication. These impurities can include things like bacteria, chemicals, or other drugs that are not intended to be present in the final product. Drug contamination can occur at any stage during the production, storage, or distribution of a medication and can potentially lead to reduced effectiveness, increased side effects, or serious health risks for patients. It is closely monitored and regulated by various health authorities to ensure the safety and efficacy of medications.

Timolol is a non-selective beta blocker drug that is primarily used to treat hypertension, angina pectoris, and glaucoma. It works by blocking the action of certain hormones such as epinephrine (adrenaline) on the heart and blood vessels, which helps to lower heart rate, reduce the force of heart muscle contraction, and decrease blood vessel constriction. These effects can help to lower blood pressure, reduce the workload on the heart, and improve oxygen supply to the heart muscle. In glaucoma treatment, timolol reduces the production of aqueous humor in the eye, thereby decreasing intraocular pressure.

The medical definition of Timolol is:

Timolol (tim-oh-lol) is a beta-adrenergic receptor antagonist used to treat hypertension, angina pectoris, and glaucoma. It works by blocking the action of epinephrine on the heart and blood vessels, which results in decreased heart rate, reduced force of heart muscle contraction, and decreased blood vessel constriction. In glaucoma treatment, timolol reduces aqueous humor production, thereby decreasing intraocular pressure. Timolol is available as an oral tablet, solution for injection, and ophthalmic solution.

Intraocular pressure (IOP) is the fluid pressure within the eye, specifically within the anterior chamber, which is the space between the cornea and the iris. It is measured in millimeters of mercury (mmHg). The aqueous humor, a clear fluid that fills the anterior chamber, is constantly produced and drained, maintaining a balance that determines the IOP. Normal IOP ranges from 10-21 mmHg, with average values around 15-16 mmHg. Elevated IOP is a key risk factor for glaucoma, a group of eye conditions that can lead to optic nerve damage and vision loss if not treated promptly and effectively. Regular monitoring of IOP is essential in diagnosing and managing glaucoma and other ocular health issues.

Therapeutic equivalence refers to the concept in pharmaceutical medicine where two or more medications are considered to be equivalent in clinical efficacy and safety profiles. This means that they can be used interchangeably to produce the same therapeutic effect.

Two products are deemed therapeutically equivalent if they contain the same active ingredient(s), are available in the same dosage form and strength, and have been shown to have comparable bioavailability, which is a measure of how much and how quickly a drug becomes available for use in the body.

It's important to note that therapeutic equivalence does not necessarily mean that the medications are identical or have identical excipients (inactive ingredients). Therefore, patients who may have sensitivities or allergies to certain excipients should still consult their healthcare provider before switching between therapeutically equivalent medications.

In many countries, including the United States, the Food and Drug Administration (FDA) maintains a list of therapeutic equivalence evaluations for generic drugs, known as the "Orange Book." This resource helps healthcare providers and patients make informed decisions about using different versions of the same medication.

Topical administration refers to a route of administering a medication or treatment directly to a specific area of the body, such as the skin, mucous membranes, or eyes. This method allows the drug to be applied directly to the site where it is needed, which can increase its effectiveness and reduce potential side effects compared to systemic administration (taking the medication by mouth or injecting it into a vein or muscle).

Topical medications come in various forms, including creams, ointments, gels, lotions, solutions, sprays, and patches. They may be used to treat localized conditions such as skin infections, rashes, inflammation, or pain, or to deliver medication to the eyes or mucous membranes for local or systemic effects.

When applying topical medications, it is important to follow the instructions carefully to ensure proper absorption and avoid irritation or other adverse reactions. This may include cleaning the area before application, covering the treated area with a dressing, or avoiding exposure to sunlight or water after application, depending on the specific medication and its intended use.

The conjunctiva is the mucous membrane that lines the inner surface of the eyelids and covers the front part of the eye, also known as the sclera. It helps to keep the eye moist and protected from irritants. The conjunctiva can become inflamed or infected, leading to conditions such as conjunctivitis (pink eye).

The cornea is the clear, dome-shaped surface at the front of the eye. It plays a crucial role in focusing vision. The cornea protects the eye from harmful particles and microorganisms, and it also serves as a barrier against UV light. Its transparency allows light to pass through and get focused onto the retina. The cornea does not contain blood vessels, so it relies on tears and the fluid inside the eye (aqueous humor) for nutrition and oxygen. Any damage or disease that affects its clarity and shape can significantly impact vision and potentially lead to blindness if left untreated.

Antihypertensive agents are a class of medications used to treat high blood pressure (hypertension). They work by reducing the force and rate of heart contractions, dilating blood vessels, or altering neurohormonal activation to lower blood pressure. Examples include diuretics, beta blockers, ACE inhibitors, ARBs, calcium channel blockers, and direct vasodilators. These medications may be used alone or in combination to achieve optimal blood pressure control.

Ocular hypertension is a medical condition characterized by elevated pressure within the eye (intraocular pressure or IOP), which is higher than normal but not necessarily high enough to cause any visible damage to the optic nerve or visual field loss. It serves as a significant risk factor for developing glaucoma, a sight-threatening disease.

The normal range of intraocular pressure is typically between 10-21 mmHg (millimeters of mercury). Ocular hypertension is often defined as an IOP consistently above 21 mmHg, although some studies suggest that even pressures between 22-30 mmHg may not cause damage in all individuals. Regular monitoring and follow-up with an ophthalmologist are essential for people diagnosed with ocular hypertension to ensure early detection and management of any potential glaucomatous changes. Treatment options include medications, laser therapy, or surgery to lower the IOP and reduce the risk of glaucoma onset.

The corneal epithelium is the outermost layer of the cornea, which is the clear, dome-shaped surface at the front of the eye. It is a stratified squamous epithelium, consisting of several layers of flat, scale-like cells that are tightly packed together. The corneal epithelium serves as a barrier to protect the eye from microorganisms, dust, and other foreign particles. It also provides a smooth surface for the refraction of light, contributes to the maintenance of corneal transparency, and plays a role in the eye's sensitivity to touch and pain. The corneal epithelium is constantly being renewed through the process of cell division and shedding, with new cells produced by stem cells located at the limbus, the border between the cornea and the conjunctiva.

Non-steroidal anti-inflammatory agents (NSAIDs) are a class of medications that reduce pain, inflammation, and fever. They work by inhibiting the activity of cyclooxygenase (COX) enzymes, which are involved in the production of prostaglandins, chemicals that contribute to inflammation and cause blood vessels to dilate and become more permeable, leading to symptoms such as pain, redness, warmth, and swelling.

NSAIDs are commonly used to treat a variety of conditions, including arthritis, muscle strains and sprains, menstrual cramps, headaches, and fever. Some examples of NSAIDs include aspirin, ibuprofen, naproxen, and celecoxib.

While NSAIDs are generally safe and effective when used as directed, they can have side effects, particularly when taken in large doses or for long periods of time. Common side effects include stomach ulcers, gastrointestinal bleeding, and increased risk of heart attack and stroke. It is important to follow the recommended dosage and consult with a healthcare provider if you have any concerns about using NSAIDs.

The eye is the organ of sight, primarily responsible for detecting and focusing on visual stimuli. It is a complex structure composed of various parts that work together to enable vision. Here are some of the main components of the eye:

1. Cornea: The clear front part of the eye that refracts light entering the eye and protects the eye from harmful particles and microorganisms.
2. Iris: The colored part of the eye that controls the amount of light reaching the retina by adjusting the size of the pupil.
3. Pupil: The opening in the center of the iris that allows light to enter the eye.
4. Lens: A biconvex structure located behind the iris that further refracts light and focuses it onto the retina.
5. Retina: A layer of light-sensitive cells (rods and cones) at the back of the eye that convert light into electrical signals, which are then transmitted to the brain via the optic nerve.
6. Optic Nerve: The nerve that carries visual information from the retina to the brain.
7. Vitreous: A clear, gel-like substance that fills the space between the lens and the retina, providing structural support to the eye.
8. Conjunctiva: A thin, transparent membrane that covers the front of the eye and the inner surface of the eyelids.
9. Extraocular Muscles: Six muscles that control the movement of the eye, allowing for proper alignment and focus.

The eye is a remarkable organ that allows us to perceive and interact with our surroundings. Various medical specialties, such as ophthalmology and optometry, are dedicated to the diagnosis, treatment, and management of various eye conditions and diseases.

Glaucoma is a group of eye conditions that damage the optic nerve, often caused by an abnormally high pressure in the eye (intraocular pressure). This damage can lead to permanent vision loss or even blindness if left untreated. The most common type is open-angle glaucoma, which has no warning signs and progresses slowly. Angle-closure glaucoma, on the other hand, can cause sudden eye pain, redness, nausea, and vomiting, as well as rapid vision loss. Other less common types of glaucoma also exist. While there is no cure for glaucoma, early detection and treatment can help slow or prevent further vision loss.

"Macaca fascicularis" is the scientific name for the crab-eating macaque, also known as the long-tailed macaque. It's a species of monkey that is native to Southeast Asia. They are called "crab-eating" macaques because they are known to eat crabs and other crustaceans. These monkeys are omnivorous and their diet also includes fruits, seeds, insects, and occasionally smaller vertebrates.

Crab-eating macaques are highly adaptable and can be found in a wide range of habitats, including forests, grasslands, and wetlands. They are also known to live in close proximity to human settlements and are often considered pests due to their tendency to raid crops and steal food from humans.

These monkeys are social animals and live in large groups called troops. They have a complex social structure with a clear hierarchy and dominant males. Crab-eating macaques are also known for their intelligence and problem-solving abilities.

In medical research, crab-eating macaques are often used as animal models due to their close genetic relationship to humans. They are used in studies related to infectious diseases, neuroscience, and reproductive biology, among others.

The double-blind method is a study design commonly used in research, including clinical trials, to minimize bias and ensure the objectivity of results. In this approach, both the participants and the researchers are unaware of which group the participants are assigned to, whether it be the experimental group or the control group. This means that neither the participants nor the researchers know who is receiving a particular treatment or placebo, thus reducing the potential for bias in the evaluation of outcomes. The assignment of participants to groups is typically done by a third party not involved in the study, and the codes are only revealed after all data have been collected and analyzed.

Fluorescein angiography is a medical diagnostic procedure used in ophthalmology to examine the blood flow in the retina and choroid, which are the inner layers of the eye. This test involves injecting a fluorescent dye, Fluorescein, into a patient's arm vein. As the dye reaches the blood vessels in the eye, a specialized camera takes rapid sequences of photographs to capture the dye's circulation through the retina and choroid.

The images produced by fluorescein angiography can help doctors identify any damage to the blood vessels, leakage, or abnormal growth of new blood vessels. This information is crucial in diagnosing and managing various eye conditions such as age-related macular degeneration, diabetic retinopathy, retinal vein occlusions, and inflammatory eye diseases.

It's important to note that while fluorescein angiography is a valuable diagnostic tool, it does carry some risks, including temporary side effects like nausea, vomiting, or allergic reactions to the dye. In rare cases, severe adverse reactions can occur, so patients should discuss these potential risks with their healthcare provider before undergoing the procedure.

I believe there may be some confusion in your question. "Rabbits" is a common name used to refer to the Lagomorpha species, particularly members of the family Leporidae. They are small mammals known for their long ears, strong legs, and quick reproduction.

However, if you're referring to "rabbits" in a medical context, there is a term called "rabbit syndrome," which is a rare movement disorder characterized by repetitive, involuntary movements of the fingers, resembling those of a rabbit chewing. It is also known as "finger-chewing chorea." This condition is usually associated with certain medications, particularly antipsychotics, and typically resolves when the medication is stopped or adjusted.

A drug interaction is the effect of combining two or more drugs, or a drug and another substance (such as food or alcohol), which can alter the effectiveness or side effects of one or both of the substances. These interactions can be categorized as follows:

1. Pharmacodynamic interactions: These occur when two or more drugs act on the same target organ or receptor, leading to an additive, synergistic, or antagonistic effect. For example, taking a sedative and an antihistamine together can result in increased drowsiness due to their combined depressant effects on the central nervous system.
2. Pharmacokinetic interactions: These occur when one drug affects the absorption, distribution, metabolism, or excretion of another drug. For example, taking certain antibiotics with grapefruit juice can increase the concentration of the antibiotic in the bloodstream, leading to potential toxicity.
3. Food-drug interactions: Some drugs may interact with specific foods, affecting their absorption, metabolism, or excretion. An example is the interaction between warfarin (a blood thinner) and green leafy vegetables, which can increase the risk of bleeding due to enhanced vitamin K absorption from the vegetables.
4. Drug-herb interactions: Some herbal supplements may interact with medications, leading to altered drug levels or increased side effects. For instance, St. John's Wort can decrease the effectiveness of certain antidepressants and oral contraceptives by inducing their metabolism.
5. Drug-alcohol interactions: Alcohol can interact with various medications, causing additive sedative effects, impaired judgment, or increased risk of liver damage. For example, combining alcohol with benzodiazepines or opioids can lead to dangerous levels of sedation and respiratory depression.

It is essential for healthcare providers and patients to be aware of potential drug interactions to minimize adverse effects and optimize treatment outcomes.

Prospective studies, also known as longitudinal studies, are a type of cohort study in which data is collected forward in time, following a group of individuals who share a common characteristic or exposure over a period of time. The researchers clearly define the study population and exposure of interest at the beginning of the study and follow up with the participants to determine the outcomes that develop over time. This type of study design allows for the investigation of causal relationships between exposures and outcomes, as well as the identification of risk factors and the estimation of disease incidence rates. Prospective studies are particularly useful in epidemiology and medical research when studying diseases with long latency periods or rare outcomes.

Isotonic solutions are defined in the context of medical and physiological sciences as solutions that contain the same concentration of solutes (dissolved particles) as another solution, usually the bodily fluids like blood. This means that if you compare the concentration of solute particles in two isotonic solutions, they will be equal.

A common example is a 0.9% sodium chloride (NaCl) solution, also known as normal saline. The concentration of NaCl in this solution is approximately equal to the concentration found in the fluid portion of human blood, making it isotonic with blood.

Isotonic solutions are crucial in medical settings for various purposes, such as intravenous (IV) fluids replacement, wound care, and irrigation solutions. They help maintain fluid balance, prevent excessive water movement across cell membranes, and reduce the risk of damaging cells due to osmotic pressure differences between the solution and bodily fluids.

"Pharmaceutical solutions" is a term that refers to medications or drugs that are formulated in a liquid state, as opposed to solid forms like tablets or capsules. These solutions are typically created by dissolving the active pharmaceutical ingredient (API) in a solvent, such as water or ethanol, along with other excipients that help stabilize and preserve the solution.

Pharmaceutical solutions can be administered to patients through various routes, including oral, intravenous, subcutaneous, or intramuscular injection, depending on the desired site of action and the specific properties of the drug. Some examples of pharmaceutical solutions include antibiotic infusions, pain medications, and electrolyte replacement drinks.

It's important to note that the term "pharmaceutical solutions" can also refer more broadly to the process of developing and manufacturing drugs, as well as to the industry as a whole. However, in a medical context, it most commonly refers to liquid medications.

In the field of medicine, "time factors" refer to the duration of symptoms or time elapsed since the onset of a medical condition, which can have significant implications for diagnosis and treatment. Understanding time factors is crucial in determining the progression of a disease, evaluating the effectiveness of treatments, and making critical decisions regarding patient care.

For example, in stroke management, "time is brain," meaning that rapid intervention within a specific time frame (usually within 4.5 hours) is essential to administering tissue plasminogen activator (tPA), a clot-busting drug that can minimize brain damage and improve patient outcomes. Similarly, in trauma care, the "golden hour" concept emphasizes the importance of providing definitive care within the first 60 minutes after injury to increase survival rates and reduce morbidity.

Time factors also play a role in monitoring the progression of chronic conditions like diabetes or heart disease, where regular follow-ups and assessments help determine appropriate treatment adjustments and prevent complications. In infectious diseases, time factors are crucial for initiating antibiotic therapy and identifying potential outbreaks to control their spread.

Overall, "time factors" encompass the significance of recognizing and acting promptly in various medical scenarios to optimize patient outcomes and provide effective care.

Treatment outcome is a term used to describe the result or effect of medical treatment on a patient's health status. It can be measured in various ways, such as through symptoms improvement, disease remission, reduced disability, improved quality of life, or survival rates. The treatment outcome helps healthcare providers evaluate the effectiveness of a particular treatment plan and make informed decisions about future care. It is also used in clinical research to compare the efficacy of different treatments and improve patient care.

"Travoprost ophthalmic Use During Pregnancy". Drugs.com. 8 October 2019. Retrieved 16 May 2020. "Travatan EPAR". European ... September 2011). "Travatan Z (travoprost) solution". DailyMed. Bethesda, MD: U.S. National Library of Medicine. Retrieved 2011- ... September 2011). "Travatan - travoprost solution". DailyMed. Bethesda, MD: U.S. National Library of Medicine. Retrieved 2011-09 ... AHFS Consumer Medication Information (2011-01-01). "Travoprost Ophthalmic". MedlinePlus. Bethesda, MD: U.S. National Library of ...
"GLANATEC® ophthalmic solution 0.4% , D.Western Therapeutics Institute, Inc". D.Western Therapeutics Institute, Inc. Retrieved ... equivalent to 4 g of ripasudil per 1000 mL of solution. The solution is developed, marketed, and distributed by Kowa ... Glanatec, the trade name of the approved formulation, takes the form of an eye drop solution of 0.4% ripasudil, ...
McCormack PL (July 2011). "Ketorolac 0.45% ophthalmic solution". Drugs & Aging. 28 (7): 583-9. doi:10.2165/11207450-000000000- ...
"Chibroxin (Norfloxacin) Ophthalmic solution" (PDF). Merck Sharp & Dohme. USA: FDA. September 2000. Arabyat RM, Raisch DW, McKoy ...
"Trifluridine Ophthalmic Solution, 1%" (PDF). Retrieved 2007-03-24. (CS1 German-language sources (de), Articles with short ...
"Bimatoprost solution/ drops". DailyMed. 18 September 2019. Retrieved 4 January 2020. "Lumigan- bimatoprost solution/ drops". ... "Prostaglandin Analogues for Ophthalmic Use: A Review of the Comparative Clinical Effectiveness and Cost-Effectiveness". CADTH ... "Bimatoprost ophthalmic (Lumigan) Use During Pregnancy". Drugs.com. 14 October 2019. Retrieved 4 January 2020. " ...
"Xdemvy- lotilaner ophthalmic solution solution/ drops". DailyMed. 26 July 2023. Retrieved 23 August 2023. "Credelio- lotilaner ... "FDA Approves Xdemvy (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis" (Press release). Tarsus ...
"Vevye- cyclosporine ophthalmic solution solution/ drops". DailyMed. 26 May 2023. Retrieved 29 August 2023. "Ikervis". European ... It is available as an ophthalmic ointment for dogs called Optimmune, manufactured by Intervet, which is part of Merck. It is ... A newer microemulsion, orally-administered formulation, Neoral, is available as a solution and as soft gelatin capsules. ... Clinical trial number NCT01287078 for "Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell ...
"Emadine (emedastine difumarate ophthalmic solution) 0.05%. Full Prescribing Information" (PDF). Alcon Laboratories, Inc. 6201 ... When the patients with allergic conjunctivitis were treated with 0.05% emedastine difumarate ophthalmic solution for six weeks ... "Emedastine (Ophthalmic)". The American Society of Health-System Pharmacists. Retrieved 11 February 2020. Bielory L, Lien KW, ... Benzalkonium chloride contained in the bottle of emedastine solution can discolor soft contact lenses, so people who wear ...
"Lastacaft (alcaftadine ophthalmic solution 0.25%)" (PDF). Drug Use Review. U.S. Food and Drug Administration. 21 June 2012. ... Greiner JV, Edwards-Swanson K, Ingerman A (January 2011). "Evaluation of alcaftadine 0.25% ophthalmic solution in acute ... "Drug Approval Package: Lastacaft (alcaftadine) Ophthalmic Solution NDA #022134". U.S. Food and Drug Administration (FDA). 24 ... Ketotifen "Alcaftadine ophthalmic (Lastacaft) Use During Pregnancy". Drugs.com. 11 October 2019. Retrieved 10 June 2020. " ...
"ALPHAGAN (brimonidine tartrate ophthalmic solution)" (PDF). fda.gov. 2016. "Allergan discloses economic impact of Cincinnati ... In 1996, Allergan received FDA approval for Alphagan ophthalmic solution for open-angle glaucoma and ocular hypertension. In ...
"cyclopentolate hydrochloride solution - ophthalmic, Cyclogyl, Cylate, Pentolair". Retrieved June 15, 2012. John P.Whitcher; ... 2009). Paenteral ophthalmic topicamide or cyclopentolate protects rats from lethal organophosphate poisoning. American Journal ... The potential for mental status changes associated with systemic absorption of anticholinergic ophthalmic medication: Concerns ...
"Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% - Sterile" (PDF). Akorn. Archived from the original (PDF) on 3 March ...
"Santen and UBE Received FDA Approval for Omlonti (Omidenepag Isopropyl Ophthalmic Solution) 0.002% for the Reduction of ... Duggan S (December 2018). "Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval". Drugs. 78 (18): 1925-1929. ... "Omlonti- omidenepag isopropyl solution/ drops". DailyMed. 30 September 2022. Retrieved 16 October 2022. "Drug Approval Package ...
2006). Xalatan (latanoprost ophthalmic solution) 0.005% (50 μg/mL). Accessed 5 Feb 2011. Facial Neurological Examination from ... In animal studies using four times the therapeutic concentration of the ophthalmic solution latanoprost, the size of the ...
... solution". DailyMed. 1 September 2022. Retrieved 21 January 2023. "Iheezo- chloroprocaine hydrochloride ophthalmic gel gel". ... Sintetica Limited (9 March 2017). "Ampres 10 mg/ml solution for injection". EMC. Archived from the original on 19 August 2019. ... mandibular nerve block or maxillary nerve block for dental anesthesia, ophthalmic anesthesia via infraorbital nerve block, ... "Nesacaine- chloroprocaine hydrochloride injection, solution Nesacaine MPF- chloroprocaine hydrochloride injection, ...
"Alcon's Newest Antibiotic, Vigamox Ophthalmic Solution, Earns FDA Approval". Infection Control Today. Alcon. 22 June 2003. ...
It is available[citation needed] as a 0.1% ophthalmic solution. It is no longer available in the United States. Use in narrow- ...
"Hyalase 1500 I.U. Powder for Solution for Injection/Infusion or Hyaluronidase 1500 I.U. Powder for Solution for Injection/ ... Common applications are ophthalmic surgery, in combination with local anesthetics. It also increases the absorption rate of ... "Hydase- hyaluronidase injection, solution". DailyMed. 16 November 2015. Retrieved 1 May 2020. "Drug Approval Package: Vitrase ( ... "HyQvia 100 mg/ml solution for infusion for subcutaneous use - Summary of Product Characteristics (SmPC)". (emc). 15 January ...
Natamycin ophthalmic suspension is the drug of choice for filamentous fungal infection. Fluconazole ophthalmic solution is ... ReNu with MoistureLoc brand of soft contact lens solutions made headlines regarding a report from the United States Centers for ... an old disease with modern nanotechnological solutions". In Rai, Mahendra; Occhiutto, Marcelo Luis (eds.). Mycotic Keratitis. ...
Customers include ophthalmic surgeons, eye clinics, laser centers, and university hospitals. Three months after announcing its ... "SCHWIND eye-tech-solutions". Adagia Partnners. Retrieved 2022-12-24. "Adagia Partners acquires Schwind Eye-Tech-Solutions, a ... SCHWIND eye-tech-solutions GmbH develops, produces and markets devices for the treatment of ametropiae and corneal diseases ... Titmus Eurocon was sold in 1982 to the Swiss group Ciba Geigy (Novartis). In the following years, Schwind eye-tech-solutions ...
2015). Sulfacetamide Sodium 10% and Prednisolone Sodium Phosphate 0.25% Ophthalmic Solution. Naik PN (2008). "Mechanistic study ... Sulfacetamide as a medicine is available as solution, eye drops, lotion, and powder. It can also be found in the form of the ... It also has anti-inflammatory properties when used to treat blepharitis or conjunctivitis (in eye-drop solution). It is ... Part 2: Spectrophotometric evaluation of decomposition products of UV-irradiated solutions of sulphacetamide". Die Pharmazie. ...
Multipurpose solutions The main attraction of multipurpose solutions is that the same solution can clean, rinse, disinfect and ... Ophthalmic and Physiological Optics. 27 (1): 11-21. doi:10.1111/j.1475-1313.2006.00427.x. hdl:10397/22844. PMID 17239186. S2CID ... Saline solution Sterile saline is used for rinsing the lens after cleaning and preparing it for insertion. Saline solutions do ... There is preliminary research on creating a new multipurpose solution that kills amoeba. Hydrogen peroxide contact solutions ...
There was a reduction in itchiness at all-time points for both ophthalmic solutions. The study concluded that bepotastine ... A Phase III clinical trial was carried out in 2010 to evaluate the effectiveness of bepotastine besilate ophthalmic solutions ... Bepotastine is available as an ophthalmic solution and oral tablet. It is a direct H1-receptor antagonist that inhibits the ... "Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis". ...
"Drug Approval Package: Altafluor Benox (fluorescein sodium and benoxinate hydrochloride ophthalmic solution)". U.S. Food and ... "Anatera 100mg/ml solution for injection - Summary of Product Characteristics (SmPC)". (emc). 10 February 2020. Retrieved 11 ... "Fluorescein sodium 100 mg/ml, solution for injection - Summary of Product Characteristics (SmPC)". (emc). 16 January 2018. ... Duvall, Brian; Kershner, Robert M. (2006). Ophthalmic Medications and Pharmacology. pp. 151-8. ISBN 9781556427503. PMID 9883136 ...
It is formulated as a 3% ophthalmic solution of the tetrasodium salt. Its mechanism of action involves agonism of the P2Y2 ...
... or for use during ophthalmic surgery. It is generally administered as an ophthalmic solution (i.e., eye drops). Carbachol ... Carbachol is primarily used in the treatment of glaucoma, but it is also used during ophthalmic surgery. Carbachol eyedrops are ... It is primarily used for various ophthalmic purposes, such as for treating glaucoma, ...
"Akorn (AKRX) Receives ANDA Approval from FDA for Bimatoprost Ophthalmic Solution, 0.03%". StreetInsider.com. Retrieved 2018-10- ... for Bimatoprost Ophthalmic Solution, 0.03%. On May 21, 2020, Akorn filed for Chapter 11 bankruptcy and entered in to a ...
McLaurin E, Cavet ME, Gomes PJ, Ciolino JB (March 2018). "Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular ... Moreover, to treat allergic conjunctivitis, tetryzoline can be combined in a solution with antazoline. In a healthy person, the ... Al-Abri SA, Yang HS, Olson KR (December 2014). "Unintentional pediatric ophthalmic tetrahydrozoline ingestion: case files of ...
A non-ointment form of ophthalmic solution is also available for eye infections. Bacitracin is a narrow-spectrum antibiotic. It ...
Buy Latanoprost Ophthalmic Solution and other Antibiotic Eye Drops & Ointments from top brands at 1800PetMeds and save. Free ...
... is a topical eye medication in liquid drop form. It can treat conditions such as dry eye syndrome, corneal ... What are ophthalmic solutions used for?. Ophthalmic solutions are used to treat conditions such as:. *. Eye infections, ... How to use ophthalmic solutions. Its important to use ophthalmic solutions correctly to ensure your treatment is successful. ... Types of ophthalmic solutions. Several types of ophthalmic solutions are available. Each treats a specific condition, from ...
Tobramycin Ophthalmic Solution USP, 0.3 % - Bottle Label:. Tobramycin Ophthalmic Solution USP, 0.3 % - Carton Label:. ... TOBRAMYCIN OPHTHALMIC SOLUTION solution/ drops. To receive this label RSS feed. Copy the URL below and paste it into your RSS ... TOBRAMYCIN OPHTHALMIC SOLUTION solution/ drops. If this SPL contains inactivated NDCs listed by the FDA initiated compliance ... Tobramycin ophthalmic solution USP, 0.3 % is a sterile topical ophthalmic antibiotic formulation prepared specifically for ...
... 9 results. * eClinical Solutions: Exploring Market Dynamics, Opportunities, ... eClinical Solutions: Dissecting Industry Trends, Growth, and the Future of Clinical Trials eClinical solutions employ digital ... Ophthalmic Drugs Market: A Profound Exploration of Trends, Growth, and Global Forecast In recent years, aging populations and a ... Notably, solutions emphasizing higher disinfection efficiency, minimal eye irritation, and prolonged lens comfort are seeing ...
TIMOPTIC Ophthalmic Solution is supplied as a sterile, isotonic, buffered, aqueous solution of timolol maleate in two dosage ... Sterile Ophthalmic Solution TIMOPTIC is a clear, colorless to light yellow solution. ... TIMOPTIC Ophthalmic Solution is available in concentrations of 0.25 and 0.5 percent. The usual starting dose is one drop of ... TIMOPTIC Ophthalmic Solution, when applied topically on the eye, has the action of reducing elevated as well as normal ...
... - Physicians PDR ... How Supplied: Carteolol Hydrochloride Ophthalmic Solution, 1% is supplied as a sterile ophthalmic solution in a plastic bottle ... Description: Carteolol Hydrochloride Ophthalmic Solution, 1%, is a nonselective beta-adrenoceptor blocking agent for ophthalmic ... Dosage and Administration: The usual dose is one drop of carteolol hydrochloride ophthalmic solution, 1%, in the affected eye(s ...
Mydfrin Ophthalmic Solution is used to dilate the pupils for eye examinations and to treat certain eye conditions. ...
Ketorolac Tromethamine Ophthalmic Solution) may treat, side effects, dosage, drug interactions, warnings, patient labeling, ... ACUVAIL (ketorolac tromethamine ophthalmic solution) 0.45% is available as a sterile solution supplied in clear, LDPE, single- ... The osmolality of ACUVAIL® solution is approximately 285 mOsml/kg.. Each mL of ACUVAIL® ophthalmic solution contains: Active: ... ACUVAIL ophthalmic solution may be administered in conjunction with other topical ophthalmic medications such as alpha-agonists ...
Gentocin Durafilm Ophthalmic Solution, 5 ml at PetSmart. Shop all pharmacy ear & eye care online ...
Dextran 70/Hydromellose Ophthalmic Solution 0.1%/0.3% Dextran 70/Hydromellose Ophthalmic Solution 0.1%/0.3%. For dry eyes. ...
The FDA has granted approval for an abbreviated new drug application to market a generic version of azelastine ophthalmic ... solution 0.05% (Optivar, Meda Pharmaceuticals), according to Sun Pharmaceutical Industries. ... to market a generic version of azelastine ophthalmic solution 0.05% (Optivar, Meda Pharmaceuticals), according to Sun ... FDA has granted approval for an abbreviated new drug application to market a generic version of azelastine ophthalmic solution ...
Vantage is a provider of mobilized surgical solutions. ... Ophthalmic Surgical Solutions, into the Vantage family and are ... Vantage Surgical Solutions, which is backed by Pharos Capital, has acquired Kansas-based Ophthalmic Surgical Solutions, a ... Home News Briefs Pharos Capital-backed Vantage Surgical Solutions acquires Ophthalmic Surgical Solutions ... Pharos Capital-backed Vantage Surgical Solutions acquires Ophthalmic Surgical Solutions. Vantage is a provider of mobilized ...
Brimonidine Tartrate Ophthalmic Solution: Brimonidine belongs to the family of medications known as alpha-2-adrenergic receptor ... For brimonidine 0.15% ophthalmic drops, the recommended dose for adults is one drop of solution into the affected eye(s) 3 ... Each mL of sterile ophthalmic solution contains brimonidine tartrate 2 mg (0.2%). Nonmedicinal ingredients: benzalkonium ... The usual recommended dose for adults is one drop of brimonidine 0.2% solution into the affected eye(s) twice daily, ...
Free coupons for pazeo ophthalmic solution. Discounts up to 80% off the retail price. ... Compare Pazeo ophthalmic solution 0.7 % prices from verified online pharmacies or local U.S. pharmacies. ... Pazeo Ophthalmic Solution Prices Compare Pazeo Ophthalmic Solution prices available at Canadian and international online ... Compare Pazeo Ophthalmic Solution prices available at Canadian and international online pharmacies with local U.S. pharmacy ...
Buy from a wide range of Sodium Hyaluronate Ophthalmic Solution online. ... Find Sodium Hyaluronate Ophthalmic Solution manufacturers, suppliers, dealers & latest prices from top companies in India. ... Sodium Hyaluronate Ophthalmic Solution. Bimatoprost Ophthalmic Solution Eye Drop. Pilocar Eye Drops. Latanoprost Ophthalmic Eye ... Sodium Hyaluronate Ophthalmic Solution. Who are the top sodium hyaluronate ophthalmic solution manufacturers in India?. - ...
Remove extra solution around the eye with a tissue and wash your hands to remove any medicine that may be on them. ...
In an increasingly competitive market environment, Apotex continually strives to introduce quality, affordable medicines to consumers.
Opthalmic Solution 15ml online at Emergency Medical Products (EMP) - your source for emergency medical supplies. ...
Pharmacy Times offers the latest news and insights for the pharmacy professional and solutions that impact the everyday ... Upsher-Smith Expands Ophthalmic Portfolio With Launch of Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution May 2, ... Please refer to full Prescribing Information for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution here. You can ... The brimonidine tartrate and timolol maleate ophthalmic solution market had U.S. sales of approximately $392 million for the 12 ...
Brimonidine Tartrate Ophthalmic Solution is an alpha-adrenergic receptor agonist indicated for the reduction of elevated ... The six lots of Brimonidine Tartrate Ophthalmic Solution, 0.15% can be identified by national drug code numbers stated on the ... Apotex is issuing a voluntary recall at the consumer level for six lots of Brimonidine Tartrate Ophthalmic Solution, 0.15%, ... Voluntary Nationwide Recall of Brimonidine Tartrate Ophthalmic Solution, 0.15% .social-ris-container { display: flex; justify- ...
Azithromycin Ophthalmic Solution (AzaSite). Azithromycin Eye Drops (AzaSite) versus .... *Azithromycin Ophthalmic vs Tobramycin ... compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis ... Time while the concentration of antibiotic solution was maintained well above the minimum inhibitory concentration required for ... Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% ...
Betaxolol HCl Ophthalmic Solution prescription and dosage sizes information for physicians and healthcare professionals. ... Betaxolol Hcl Ophthalmic Solution Clinical Trials. See Literature. Betaxolol Hcl Ophthalmic Solution Note. Notes Formerly known ... Betaxolol Hcl Ophthalmic Solution Boxed Warnings. Not Applicable. Betaxolol Hcl Ophthalmic Solution Warnings/Precautions. ... Betaxolol Hcl Ophthalmic Solution Pharmacokinetics. See Literature. Betaxolol Hcl Ophthalmic Solution Interactions. ...
In an increasingly competitive market environment, Apotex continually strives to introduce quality, affordable medicines to consumers.
0.3%, 5ml Gentamicin ophthalmic solution is a generic version of Garamycin. It belongs to a class of drugs known as ... gentamicin-ophthalmic-solution-0-3-5ml" width="100%" height="400" frameborder="0" marginheight="0" marginwidth="0">. *} ...
The company also offers Sodium Carboxymethyl Cellulose Ophthalmic Solution PCD Pharma Franchise. ... this solution comes with the branding of CONITEAR in packing of 10 ml. ... Contact the best Sodium Carboxymethyl Cellulose Ophthalmic Solution manufacturer and supplier, ... Be the first to review "Sodium Carboxymethyl Cellulose Ophthalmic Solution". Your email address will not be published. Required ...
Manufacture of Ophthalmic and Contact Lens Solutions. View PDF Contact lens solutions include different products which perform ... Ophthalmic solutions include safety eyewash and prescription preparations as well as "over the counter" medicinal products. ... These solutions tend to have a similar base formulation: a saline solution (typically 5%) with a range of added ingredients ... The Solution These problems can be overcome and process times can be dramatically cut by using a Silverson High Shear mixer. ...
Compare prednisolone ophthalmic prices, print discount coupons, find manufacturer promotions, copay cards and patient ... Prednisolone ophthalmic prices. Ophthalmic Solution. sodium phosphate 1% prednisolone ophthalmic ophthalmic solution ... prednisone, diclofenac ophthalmic, cetirizine ophthalmic, dexamethasone ophthalmic, triamcinolone, ketorolac ophthalmic, ... Prednisolone ophthalmic Prices, Coupons and Patient Assistance Programs. Prednisolone ophthalmic is a member of the ophthalmic ...
Upgrades for ophthalmic coating machines from Bühler Leybold Optics cover equipment, control systems and accessories to reduce ... We can fit a new industrial PC and OptiControl solution in a 3-day installation, giving you the latest control and ... Upgrade your ophthalmic coating machine. Our customized upgrade options for your Syrus series or Leybold Optics CCS series will ... Upgrade your ophthalmic coating machine. Our customized upgrade options for your Syrus series or Leybold Optics CCS series will ...
... *Home. *Products tagged "Hydroxypropyl Methyl Cellulose Ophthalmic Solution ...

No FAQ available that match "ophthalmic solutions"

No images available that match "ophthalmic solutions"